Burden and Temporal Trends of Osteoarthritis in Germany from 1990 to 2021, with Projections to 2041: Findings from the Global Burden of Disease Study Authors: Mohammad Ali Alshrouf Published: 2026 ABSTRACT BackgroundOsteoarthritis (OA) is a leading cause of disability globally, particularly affecting aging populations. This study assessed temporal trends in OA burden in Germany from 1990 to 2021 and projected future burden to 2041.MethodsA secondary analysis of the Global Burden of Disease (GBD) 2021 data was conducted. Metrics analyzed included age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and disability-adjusted life years (DALYs). Temporal trends were assessed using estimated annual percentage change (EAPC) and joinpoint regression. Decomposition analysis was used to examine the main drivers of the increase in incidence. Pearson’s correlation assessed temporal co-variation with the Sociodemographic Index (SDI), and ARIMA models projected burden to 2041.ResultsBetween 1990 and 2021, incident OA cases increased by 36%, prevalent cases by 48%, and DALYs by 49%. Across all three measures, the relative increase was greater in males than in females (incidence: 50% vs 28%; prevalence: 73% vs 36%; DALYs: 74% vs 37%). Despite these steeper relative increases in males, females had higher absolute burden in 2021 for incidence, prevalence, and DALYs (468,653 vs 319,059; 7,571,715 vs 4,696,892; and 272,903 vs 164,888, respectively). Knee OA was the dominant subtype and accounted for the highest incidence and prevalence, exceeding 7.2 million prevalent cases in 2021. Germany’s DALY rates exceeded global rates in all age groups except 45–59 years. Decomposition analysis suggested that the increase in incidence was mainly attributable to changes in age structure (23.9%), population growth (6.4%), and epidemiologic change (5.7%). Joinpoint regression identified several significant shifts in temporal trends, with renewed increases after 2010. ASIR, ASPR, and age-standardized DALY rates (ASDaR) showed positive temporal correlations with the SDI. ARIMA projections suggested continued upward trends in ASIR, ASPR, and ASDaR attributed to OA, with projected values by 2041 reaching approximately 580.0 (95% CI: 554.7–605.3), 7309.1 (95% CI: 7110.9–7507.2), and 260.6 (95% CI: 252.3–268.9) per 100,000 persons, respectively.ConclusionThe burden of OA in Germany has increased substantially over the past three decades and is projected to continue rising through 2041. Although the relative increase in incidence was greater in males, the absolute burden remained higher in females. The projected rise in OA burden underscores the need for targeted healthcare planning and resource allocation. National strategies should account for demographic aging to support effective long-term OA management. Introduction Osteoarthritis (OA) is a degenerative joint disease and a leading cause of chronic pain and disability worldwide, particularly among older adults. It affects the spine and peripheral joints, most commonly the hands, hips, knees, and feet.1–3 OA is a multifactorial condition influenced by both non-modifiable and modifiable risk factors. Age and female sex are major determinants of disease onset and severity, while hormonal changes after menopause may further increase risk in women.4 Among modifiable factors, elevated body mass index (BMI), physical inactivity, occupational and mechanical joint loading, and prior joint injury contribute substantially to disease development and progression.1,4,5 These risk factors vary across age groups and between sexes, providing an important rationale for age- and sex-disaggregated analyses of OA burden. Globally, OA affects over 595 million people, representing 7.6% of the global population, and its prevalence is projected to increase significantly by 2050 due to population growth and aging.1 Earlier global burden analyses have shown a substantial and steadily increasing OA burden worldwide.6 As populations age, the burden of OA is expected to rise, placing increasing demands on healthcare systems.6,7 In Germany, where the proportion of individuals aged 65 and older is projected to reach 34% by 2060, understanding the burden of OA is critical for effective healthcare planning and resource allocation.8 OA not only impacts individuals’ quality of life but also contributes significantly to healthcare costs and workforce productivity losses.9 OA also encompasses anatomically and epidemiologically distinct subtypes, particularly knee, hip, and hand OA, which differ in prevalence and risk factor profiles and may require different management approaches; knee OA is the most common subtype globally and is a major contributor to OA-related disability burden.1,4,10 Current management strategies for OA include physical therapy, pharmacological treatment to control pain and inflammation; however, no therapy has yet proven effective in halting or reversing structural joint damage and in severe cases joint replacement may be necessary.3,11,12 In Germany, the 2014 data from the BARMER health insurance fund showed that 63.4% of elderly OA patients received analgesics, 43.1% physical therapy, and 5.3% joint replacements, with variations by age, sex, and comorbidities.7 Moreover, the increasing prevalence of OA, coupled with Germany’s physician shortage, poses significant challenges.13 This is further compounded by increasing demand for orthopedic and trauma care, limited hospital resources, and shortages of both medical and nursing staff.13,14 In Germany, the burden of osteoarthritis has been steadily increasing, reflecting broader demographic and epidemiological trends. Data from the InGef research database between 2015 and 2020, indicate that approximately 1 million new diagnoses of knee OA occur annually, underscoring the substantial and growing clinical burden.15 In a national health survey conducted by the Robert Koch Institute (GEDA 2014/2015-EHIS), 17.9% of adults in Germany reported having osteoarthritis in the past 12 months, with nearly half of females (48.1%) and one-third of males (31.2%) aged 65 and over affected.16 However, two important gaps remain. First, available German studies provide valuable cross-sectional prevalence estimates, and in some cases treatment data, but do not offer a comprehensive long-term age- and sex-stratified assessment of OA burden across incidence, prevalence, and disability outcomes.7,16 Second, although GBD-based studies have evaluated OA burden and projections at the global and broader international level,1,17,18 Germany-specific long-term trend analyses with forward projections remain limited. Addressing these gaps is important for identifying subgroup-specific disparities, understanding subtype patterns, and informing future healthcare planning in the context of demographic aging. This study aims to provide a comprehensive analysis of OA burden in Germany from 1990 to 2021, with a focus on age and sex disparities. Specifically, the objectives were to quantify trends in OA incidence, prevalence, and disability-adjusted life years (DALYs) in Germany from 1990 to 2021; to describe the burden by OA subtype; to examine the relationship between OA burden and the Sociodemographic Index (SDI); and to project the future burden through 2041 to inform healthcare planning and resource allocation. Methodology Overview A secondary analysis utilizing data from the GBD 2021 study was performed to assess osteoarthritis burden in Germany. The GBD 2021 represents a comprehensive international collaboration that estimates the impact of 371 diseases by age, sex, year, and geographical location across, 21 regions, and 7 super-regions spanning from 1990 to 2021.1 Key burden metrics include incidence, prevalence, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs). The methodological framework underpinning the GBD estimations has been extensively detailed in prior publications.1 The methods for GBD estimation are published elsewhere. The data utilized in this study were obtained from the publicly accessible GBD database, which compiles comprehensive health-related information from various global sources. Since this research involves secondary analysis of de-identified, publicly available datasets, formal ethical approval and informed consent were not required. Case Definitions The study considered osteoarthritis occurring at various joint locations, including the hand, hip, knee, and an additional category encompassing other joints such as the shoulder and elbow. Osteoarthritis cases involving the cervical and lumbar spine were excluded from the analysis, as these are accounted for under separate disease categories of neck pain and lower back pain within the Global Burden of Disease framework.1 Osteoarthritis cases were defined in accordance with the GBD 2021 study criteria based on International Classification of Diseases, 10th edition (ICD 10), which uses symptomatic OA (at least 1 month out of the past 12 months) confirmed by radiographic evidence classified as Kellgren-Lawrence grades 2–4. Grade 2 as the presence of one defined osteophyte in the joint, Grade 3 as several osteophytes and joint-space narrowing, and Grade 4 as the same criteria as Grade 3 plus bone deformity.1,19 Data Sources Osteoarthritis data for this study were obtained from the GBD 2021, accessed via the Global Health Data Exchange (GHDx) query tool (VizHub - GBD Results, healthdata.org). Incidence, prevalence, and DALY estimations were extracted alongside their 95% uncertainty intervals (UI). Incidence rates denote the number of new osteoarthritis cases diagnosed annually per 100,000 individuals. DALYs, representing the total healthy years lost due to disease, combine YLL and YLD (calculated by multiplying prevalence estimates by disability weights), providing a comprehensive measure of disease burden at national, regional, and global scales. The dataset covered the entire German population, stratified by sex and divided into 12 specific age groups at five-year intervals from 20 to 79 years (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79), with additional broader groups for individuals under 20 and those aged 80 and above. Sociodemographic Index (SDI) was also included as a key variable; SDI is a composite measure reflecting socioeconomic development, calculated as the geometric mean of indicators such as total fertility rate among females under 25, mean educational attainment for individuals aged 15 and older, and lag-distributed income per capita. Incorporating SDI enables contextual understanding of how social and economic factors influence disease burden, consistent with approaches in global osteoarthritis studies. Statistical Analysis Descriptive analyses were performed to examine the incidence, prevalence, and DALY rates of osteoarthritis by region, sex, and year. All estimates were age-standardized using the direct standardization method, based on the GBD standard world population updated for 2021. Age-standardized rates (ASRs) per 100,000 individuals were calculated. Estimated annual percentage change (EAPC) was computed to describe the temporal trends in studied metrics of burden among individuals with osteoarthritis. The EAPC and its 95% confidence intervals (CI) were computed as follows: First, expressed as Y = α + β X + ε, where X represents the calendar year, Y refers to the natural logarithm of the metric, and ε indicates the error term. Second, EAPC = 100 × (exp(β) – 1). For the EAPC fitting, the coefficients of the linear regression model fitted using Ordinary Least Squares (OLS) were used to estimate the significance of each indicator from 1990 to 2021. Trends were interpreted as an upward trend if the EAPC and its 95% CI were both greater than zero; a downward trend if both were less than zero; otherwise, trends were considered stable when the 95% CI included zero. Pearson correlation analysis was used to describe the temporal co-variation between OA burden metrics and the Sociodemographic Index (SDI). The decomposition analysis was performed following the approach outlined by previously published research.20 Jointpoint regression was applied to analyze the temporal trends in ASIR, ASPR, and ASDaR over the period between 1990 and 2021. Jointpoint regression was conducted using the National Cancer Institute’s Jointpoint Regression Program (version 5.0.2). This model utilizes the least squares method to estimate the changing patterns of illness rates, thus mitigating the subjectivity inherent in conventional trend analyses based on linear trends. By calculating the sum of squared residuals between the estimated and actual values, the joinpoint regression model identifies the turning point where the trend shifts.21 Trends were expressed as annual percentage change (APC) and the Z-test was used to assess whether APCs were statistically significant from zero. Trends were labeled as increasing or decreasing if the APC was significantly different from zero; otherwise, they were considered stable. Number of jointpoints was automatically determined by the software. For all metrics, log transformation using the permutation model was utilized. Population estimates for the GBD population from 1980 to 2021 were extracted from the IHME database. Estimated population estimates for the years between 2022 and 2041 were extracted from IHME reference forecasted population.22 Forecasting of the metrics of burden was constructed using an ARIMA (p,d,q) model from 2021 to 2041, an approach previously applied in GBD-based disease burden projection studies.23 The letters p, d, and q represent the order of autoregression, degree of difference, and order of moving average, respectively. The best ARIMA model was selected by minimizing Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Residual autocorrelation was assessed using the Ljung-Box Q test. MAPE values were utilized to assess the ARIMA model’s accuracy. Model validation was conducted by fitting ARIMA models on different data time frames and comparing model metrics (eg., 1990–2000, 2000–2010, 2010–2021). All analyses and data visualizations were conducted on R, version 4.3.3, using the appropriate and relevant packages. For all conducted analyses, a p-value of less than 0.05 was considered statistically significant. Results Burden of OA in Germany The total number of incidence cases of OA in Germany increased from 579,625 (UI: 515357.9–644,918.7) in 1990 to 787,712 (UI: 698574.4–873,750.1) in 2021 representing an increase of 36%. The increase was higher for males (50%) compared to females (28%). The ASIR for OA demonstrated a significant upward trend (EAPC: 0.15; 95% CI: 0.13–0.17); a trend consistent for both males and females. In terms of prevalence, the total number of cases increased by 48% from 8,283,522 (UI: 7453152.2–9,115,020.2) in 1990 to 12,268,606 (UI: 11049241.9–13,609,527.7) in 2021. The increase was also higher in males (73%) than in females (36%). ASPR demonstrated a significant upward trend (EAPC: 0.11; 95% CI: 0.09–0.13). This was mirrored across males and females. Across Germany, the total DALY attributed to OA increased from 294,049 (UI: 142784.6–593,358.3) in 1990 to 437,790 (UI: 215922.6–879,846.4) in 2021, representing a 49% increase. The burden was higher for males (74%) compared to females (37%). Age-standardized DALY rate (ASDaR) showed a significant upward trend (EAPC: 0.11; 95% CI: 0.09–0.13) mirrored across both males and females. Table 1 presents detailed data on incidence, prevalence, and DALY numbers and age-standardized rates for osteoarthritis in Germany from 1990 to 2021. Figure 1 illustrates sex-stratified temporal trends in ASIR, ASPR, and ASDaR over the study period. Figure 1ASIR, ASPR, and ASDaR of osteoarthritis in Germany between 1990 and 2021 stratified by sex.The figure contains three line graphs showing age-standardized osteoarthritis rates in Germany from 1990 to 2021, stratified by sex. The top graph shows the age-standardized incidence rate, the middle graph shows the age-standardized prevalence rate, and the bottom graph shows the age-standardized DALY rate, all per 100,000 persons. In all three panels, females have the highest rates, males have the lowest rates, and the both-sex estimate lies between them. The rates show an overall gradual increase over time, with minor fluctuations during the study period.Three line graphs showing sex-stratified age-standardized incidence, prevalence, and DALY rates of osteoarthritis in Germany from 1990 to 2021. Table 1Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis in Germany and Their Temporal Trends Between 1990 and 2021MeasureSex19902021EAPC95% CIΔNumber95%UIRate95%UINumber95%UIRate95%UIIncidenceMale213234.6188,749.6–239,287.1422.9376.1–472.4319,059.4282,274.1–357,632.4459.8408.5–5120.20.18–0.2350%IncidenceFemale366390.4325,626.2–407,484.4607.2539.3–674.9468,653416,264.9–520,769.9646.5571.8–721.70.160.13–0.1828%IncidenceBoth579625515,357.9–644,918.7520464.4–575.9787,712.4698,574.4–873,750.1553.7490.8–616.70.150.13–0.1736%PrevalenceMale2712593.12,428,885 - 3,019,195.85467.14911.3–6067.84,696,892.14,211,456 - 5,214,670.15884.15282.8–6527.40.180.16–0.2173%PrevalenceFemale5570929.15,034,454.1–6,118,266.67745.76964.4–8519.17,571,714.76,790,972.6–8,426,024.68210.47323.8–9127.90.160.15–0.1836%PrevalenceBoth8283522.27,453,152.2–9,115,020.26788.16108.5–7478.512,268,606.811,049,241.9–13,609,527.77101.56375.1–7854.60.110.09–0.1348%DALYsMale94595.945,835.2–189,764.4190.592.5 - 382164,88880,010.4–329,695.5206.3100 - 417.70.20.16–0.2374%DALYsFemale199453.396,947.3–404,270.6275.8133.6–558.5272,902.9135,610.3–547,145.4294.2145.5–591.90.180.15–0.237%DALYsBoth294049.2142,784.6–593,358.3240.3116.6–486.3437,790.9215,922.6–879,846.4252.4124.2–508.20.110.09–0.1349%Note: Δ refers to percentage change in cases between 1990 and 2021.Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. ASIR, ASPR, and ASDaR of osteoarthritis in Germany between 1990 and 2021 stratified by sex. Table 1Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis in Germany and Their Temporal Trends Between 1990 and 2021MeasureSex19902021EAPC95% CIΔNumber95%UIRate95%UINumber95%UIRate95%UIIncidenceMale213234.6188,749.6–239,287.1422.9376.1–472.4319,059.4282,274.1–357,632.4459.8408.5–5120.20.18–0.2350%IncidenceFemale366390.4325,626.2–407,484.4607.2539.3–674.9468,653416,264.9–520,769.9646.5571.8–721.70.160.13–0.1828%IncidenceBoth579625515,357.9–644,918.7520464.4–575.9787,712.4698,574.4–873,750.1553.7490.8–616.70.150.13–0.1736%PrevalenceMale2712593.12,428,885 - 3,019,195.85467.14911.3–6067.84,696,892.14,211,456 - 5,214,670.15884.15282.8–6527.40.180.16–0.2173%PrevalenceFemale5570929.15,034,454.1–6,118,266.67745.76964.4–8519.17,571,714.76,790,972.6–8,426,024.68210.47323.8–9127.90.160.15–0.1836%PrevalenceBoth8283522.27,453,152.2–9,115,020.26788.16108.5–7478.512,268,606.811,049,241.9–13,609,527.77101.56375.1–7854.60.110.09–0.1348%DALYsMale94595.945,835.2–189,764.4190.592.5 - 382164,88880,010.4–329,695.5206.3100 - 417.70.20.16–0.2374%DALYsFemale199453.396,947.3–404,270.6275.8133.6–558.5272,902.9135,610.3–547,145.4294.2145.5–591.90.180.15–0.237%DALYsBoth294049.2142,784.6–593,358.3240.3116.6–486.3437,790.9215,922.6–879,846.4252.4124.2–508.20.110.09–0.1349%Note: Δ refers to percentage change in cases between 1990 and 2021.Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis in Germany and Their Temporal Trends Between 1990 and 2021 Note: Δ refers to percentage change in cases between 1990 and 2021. Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. Decomposition Analysis of Incident OA Cases The decomposition analysis showed that the increase in incident OA cases in Germany from 1990 to 2021 was primarily attributable to changes in age structure (23.9%), followed by population growth (6.4%) and epidemiologic change, reflecting changes in the underlying incidence rate (5.7%). Burden of OA Types Across Germany The incidence, prevalence, and DALYs for OA of the hip, knee, hand, and other joints increased from 1990 to 2021. Among OA subtypes, knee osteoarthritis accounted for the highest burden, with the greatest number of incident and prevalent cases in 2021, followed by hand and hip OA. Incident knee OA cases increased from 377,450 in 1990 to 518,788 in 2021 (37% increase), while hip OA incidence increased by 47% and hand OA by 27%. In terms of prevalence, knee OA remained the dominant subtype, exceeding 7.2 million cases in 2021. Across all sex-specific OA subtype measures, relative percentage increases in case numbers from 1990 to 2021 were greater in males than in females, while females continued to have higher absolute case counts in 2021. Overall age-standardized trends differed by subtype. Hip, knee, and other OA showed significant upward trends in ASIR, ASPR, and ASDaR, whereas hand OA showed a stable ASIR trend but declining ASPR and ASDaR. In sex-specific age-standardized analyses, hip, knee, and other OA increased in both sexes. Hand OA showed declining age-standardized trends in males, while females showed stable-to-slightly increasing trends. Table 2 summarizes incidence, prevalence, and DALY numbers and age-standardized rates for hip, knee, hand, and other joints osteoarthritis in Germany from 1990 to 2021. Table 2Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis of the Hip, Knee, Hand, and Other Joints in Germany and Their Temporal Trends Between 1990 and 2021MeasureSex19902021EAPC95% CIΔNumber95%UIRate95%UINumber95%UIRate95%UIOsteoarthritis HipIncidenceMale15946.112,033.3–20,530.431.423.7–40.224,696.418,766.5–32,323.936.727.7–47.20.470.43–0.5155%IncidenceFemale21111.315,733.4–27,465.135.426.4–45.129,869.522,280.9–39,334.241.931.5–53.40.530.48–0.5741%IncidenceBoth37057.427,799.8–47,985.133.625.3–42.954,56641,250.7–71,300.439.329.8–49.70.490.45–0.5247%PrevalenceMale303375226,306.2–391,313.8616.5464.6–793.9578,873440,282.5–745,195.3721.5548.7–921.40.480.44–0.5191%PrevalenceFemale490991.2371,695.7–616,635.6660496.2 - 832753,963575,095.1–945,164.1781.6591.8–985.30.530.48–0.5754%PrevalenceBoth794366.2600,408 - 1,002,066646.6491.3–819.21,332,835.91,019,704.6–1,679,999.8755575.4 - 9620.470.43–0.5168%DALYsMale9803.34515.1–19,752.619.99.1–40.118,474.58629.1–36,951.923.210.9–47.30.470.43–0.5188%DALYsFemale154437369 - 31,877.520.910 - 43.323,561.911,017.2–48,340.524.711.5–50.60.510.47–0.5653%DALYsBoth25246.311,914.1–51,975.720.69.7–42.542,036.419,613.8–85,772.724.111.3–49.10.470.42–0.5167%Osteoarthritis KneeIncidenceMale137310.4117,656.4–160,037.1272.7235.6–315.7211,179.7183,429.8–244,696.3298.9257.6–341.70.260.24–0.2954%IncidenceFemale240139.8207,276.7–278,959.4391337.5–450.2307,608.4266,774.1 - 355,788415.2359.1–480.60.160.14–0.1928%IncidenceBoth377450.2326,327.6–436,452.6335.5290.6–383.8518,788.2453,048.6–601,412.5357.4310.5 - 4070.180.16–0.1937%PrevalenceMale1541608.41,316,847.3–1,776,394.43105.22670.8–3567.72,712,274.12,326,412 - 3,082,416.23379.82919.1–3844.70.270.25–0.2976%PrevalenceFemale3355987.62,914,493.5–3,902,137.84608.93993.7–5286.64,582,395.23,955,302 - 5,311,340.34913.84230.9–5681.30.210.19–0.2237%PrevalenceBoth48975964,248,140 - 5,602,423.139893461.4–4566.27,294,669.46,310,535.7–8,362,361.84185.73634.8–4827.30.150.14–0.1649%DALYsMale49987.724,464.6–95,826.9100.449.4–194.387,124.441,742.6–174,572.9109.352.7–218.50.270.25–0.2974%DALYsFemale106577.552,684.4–210,259.5147.572.9–288.7144,459.172,379.5–286,890.9156.877.8–307.20.20.18–0.2236%DALYsBoth156565.277,307.7–311,068.612863.2–252.3231,583.5114,594 - 458,428.4134.266.1–262.60.150.14–0.1648%Osteoarthritis HandIncidenceMale40978.129,511.7–53,140.780.559.3–103.354,971.939,843.9–72,209.683.761.7–108.8−0.11−0.2 - −0.0234%IncidenceFemale80692.459,862.7 - 104,736141.7104.4 - 184100,007.274,749.2–129,745.7148110.7–191.70.040 - 0.0824%IncidenceBoth121670.589,313.8–158,238.9112.282.7–144.4154,979.1114,608 - 201,955.811687.1–149.8−0.03−0.09–0.0227%PrevalenceMale752005.6564,588.7–960,603.11515.81144 - 1931.51,271,473949,611.7–1,645,235.71577.21194.5–2040.9−0.09−0.18 - −0.0169%PrevalenceFemale1943523.91,435,301.9–2,517,284.42694.61996.8–3475.92,633,379.82,007,396 - 3,410,978.62816.72123.9–3632.20.050.01–0.0935%PrevalenceBoth2695529.52,005,424.1 - 3,477,8862199.21645.3–2814.23,904,852.82,967,342.4–5,015,839.92227.91689.9–2857.2−0.1−0.15 - −0.0445%DALYsMale24339.710,984.4–50,287.748.922 - 101.140,720.518,443.6–82,861.150.922.9–103.8−0.09−0.18 - −0.0167%DALYsFemale6146527,963.9–123,981.285.938.6–172.482,741.937,826.8–167,920.189.740.6–181.20.040 - 0.0835%DALYsBoth85804.739,004.5–172,768.970.231.8–141.3123,462.456,290.8–249,263.871.232.4 - 145−0.1−0.15 - −0.0544%Osteoarthritis OtherIncidenceMale19000.115,129.1–24,274.638.231.2–47.928,211.322,626 - 35,44240.532.5–51.80.170.15–0.1948%IncidenceFemale24446.819,786.7–30,523.739.231.5–50.531,167.925,600 - 38,344.541.333.3–52.40.170.16–0.1927%IncidenceBoth43446.934,972 - 54,791.338.731.2–49.259,379.248,161.1–73,553.440.932.7 - 520.170.16–0.1937%PrevalenceMale324091.2253,167.1–418,719.4662.8520.8–846.8581,052.6451,426.5–751,340.6710.3549.9–920.50.210.18–0.2379%PrevalenceFemale507078.6398,137.2–655,880.8678.9526 - 898707,691564,091.7–901,470.1723.9566.7–937.30.210.19–0.2240%PrevalenceBoth831169.7654,075.8–1,074,378.3672.6526.6–873.51,288,743.61,013,107.9–1,650,949.6717.5559.8–930.10.20.18–0.2255%DALYsMale10465.34847.8–21,615.421.310.0–44.018,568.68591.5–39,029.222.910.4–48.40.210.18–0.2477%DALYsFemale15967.87595 - 33,207.321.510.2–44.422,139.910,626.9–45,992.52310.9–47.40.190.17–0.2239%DALYsBoth2643312,435.9–54,922.621.510.1–44.440,708.519,054.2–85,242.322.910.7–47.80.20.17–0.2254%Note: Δ refers to percentage change in cases between 1990 and 2021.Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. Table 2Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis of the Hip, Knee, Hand, and Other Joints in Germany and Their Temporal Trends Between 1990 and 2021MeasureSex19902021EAPC95% CIΔNumber95%UIRate95%UINumber95%UIRate95%UIOsteoarthritis HipIncidenceMale15946.112,033.3–20,530.431.423.7–40.224,696.418,766.5–32,323.936.727.7–47.20.470.43–0.5155%IncidenceFemale21111.315,733.4–27,465.135.426.4–45.129,869.522,280.9–39,334.241.931.5–53.40.530.48–0.5741%IncidenceBoth37057.427,799.8–47,985.133.625.3–42.954,56641,250.7–71,300.439.329.8–49.70.490.45–0.5247%PrevalenceMale303375226,306.2–391,313.8616.5464.6–793.9578,873440,282.5–745,195.3721.5548.7–921.40.480.44–0.5191%PrevalenceFemale490991.2371,695.7–616,635.6660496.2 - 832753,963575,095.1–945,164.1781.6591.8–985.30.530.48–0.5754%PrevalenceBoth794366.2600,408 - 1,002,066646.6491.3–819.21,332,835.91,019,704.6–1,679,999.8755575.4 - 9620.470.43–0.5168%DALYsMale9803.34515.1–19,752.619.99.1–40.118,474.58629.1–36,951.923.210.9–47.30.470.43–0.5188%DALYsFemale154437369 - 31,877.520.910 - 43.323,561.911,017.2–48,340.524.711.5–50.60.510.47–0.5653%DALYsBoth25246.311,914.1–51,975.720.69.7–42.542,036.419,613.8–85,772.724.111.3–49.10.470.42–0.5167%Osteoarthritis KneeIncidenceMale137310.4117,656.4–160,037.1272.7235.6–315.7211,179.7183,429.8–244,696.3298.9257.6–341.70.260.24–0.2954%IncidenceFemale240139.8207,276.7–278,959.4391337.5–450.2307,608.4266,774.1 - 355,788415.2359.1–480.60.160.14–0.1928%IncidenceBoth377450.2326,327.6–436,452.6335.5290.6–383.8518,788.2453,048.6–601,412.5357.4310.5 - 4070.180.16–0.1937%PrevalenceMale1541608.41,316,847.3–1,776,394.43105.22670.8–3567.72,712,274.12,326,412 - 3,082,416.23379.82919.1–3844.70.270.25–0.2976%PrevalenceFemale3355987.62,914,493.5–3,902,137.84608.93993.7–5286.64,582,395.23,955,302 - 5,311,340.34913.84230.9–5681.30.210.19–0.2237%PrevalenceBoth48975964,248,140 - 5,602,423.139893461.4–4566.27,294,669.46,310,535.7–8,362,361.84185.73634.8–4827.30.150.14–0.1649%DALYsMale49987.724,464.6–95,826.9100.449.4–194.387,124.441,742.6–174,572.9109.352.7–218.50.270.25–0.2974%DALYsFemale106577.552,684.4–210,259.5147.572.9–288.7144,459.172,379.5–286,890.9156.877.8–307.20.20.18–0.2236%DALYsBoth156565.277,307.7–311,068.612863.2–252.3231,583.5114,594 - 458,428.4134.266.1–262.60.150.14–0.1648%Osteoarthritis HandIncidenceMale40978.129,511.7–53,140.780.559.3–103.354,971.939,843.9–72,209.683.761.7–108.8−0.11−0.2 - −0.0234%IncidenceFemale80692.459,862.7 - 104,736141.7104.4 - 184100,007.274,749.2–129,745.7148110.7–191.70.040 - 0.0824%IncidenceBoth121670.589,313.8–158,238.9112.282.7–144.4154,979.1114,608 - 201,955.811687.1–149.8−0.03−0.09–0.0227%PrevalenceMale752005.6564,588.7–960,603.11515.81144 - 1931.51,271,473949,611.7–1,645,235.71577.21194.5–2040.9−0.09−0.18 - −0.0169%PrevalenceFemale1943523.91,435,301.9–2,517,284.42694.61996.8–3475.92,633,379.82,007,396 - 3,410,978.62816.72123.9–3632.20.050.01–0.0935%PrevalenceBoth2695529.52,005,424.1 - 3,477,8862199.21645.3–2814.23,904,852.82,967,342.4–5,015,839.92227.91689.9–2857.2−0.1−0.15 - −0.0445%DALYsMale24339.710,984.4–50,287.748.922 - 101.140,720.518,443.6–82,861.150.922.9–103.8−0.09−0.18 - −0.0167%DALYsFemale6146527,963.9–123,981.285.938.6–172.482,741.937,826.8–167,920.189.740.6–181.20.040 - 0.0835%DALYsBoth85804.739,004.5–172,768.970.231.8–141.3123,462.456,290.8–249,263.871.232.4 - 145−0.1−0.15 - −0.0544%Osteoarthritis OtherIncidenceMale19000.115,129.1–24,274.638.231.2–47.928,211.322,626 - 35,44240.532.5–51.80.170.15–0.1948%IncidenceFemale24446.819,786.7–30,523.739.231.5–50.531,167.925,600 - 38,344.541.333.3–52.40.170.16–0.1927%IncidenceBoth43446.934,972 - 54,791.338.731.2–49.259,379.248,161.1–73,553.440.932.7 - 520.170.16–0.1937%PrevalenceMale324091.2253,167.1–418,719.4662.8520.8–846.8581,052.6451,426.5–751,340.6710.3549.9–920.50.210.18–0.2379%PrevalenceFemale507078.6398,137.2–655,880.8678.9526 - 898707,691564,091.7–901,470.1723.9566.7–937.30.210.19–0.2240%PrevalenceBoth831169.7654,075.8–1,074,378.3672.6526.6–873.51,288,743.61,013,107.9–1,650,949.6717.5559.8–930.10.20.18–0.2255%DALYsMale10465.34847.8–21,615.421.310.0–44.018,568.68591.5–39,029.222.910.4–48.40.210.18–0.2477%DALYsFemale15967.87595 - 33,207.321.510.2–44.422,139.910,626.9–45,992.52310.9–47.40.190.17–0.2239%DALYsBoth2643312,435.9–54,922.621.510.1–44.440,708.519,054.2–85,242.322.910.7–47.80.20.17–0.2254%Note: Δ refers to percentage change in cases between 1990 and 2021.Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. Incidence, Prevalence, and DALY Numbers and Age-Standardized Rates for Osteoarthritis of the Hip, Knee, Hand, and Other Joints in Germany and Their Temporal Trends Between 1990 and 2021 Note: Δ refers to percentage change in cases between 1990 and 2021. Abbreviations: UI, 95% uncertainty intervals; EAPC, Estimated annual percentage change; CI, confidence intervals. Based on GBD data, Germany’s ASIR for overall OA in 2021 was lower than that of Japan, the United Kingdom, the United States, Brazil, South Africa, and Italy, but higher than that of Saudi Arabia, Egypt, Iraq, France, and Canada, with broadly similar patterns for ASPR and ASDaR (Figure 2). Subtype-specific comparisons showed that Germany’s knee OA ASIR was lower than that of Japan, China, United States, United Kingdom, and Brazil, with ASPR and ASDaR following the same pattern (Supplementary Figure 1). For hip OA, Germany’s rates were lower than those of United States, United Kingdom, and France across all three metrics (Supplementary Figure 2). For hand OA, Germany’s rates were lower than those of Japan, United States, South Africa, Canada, Brazil, Italy, and the United Kingdom, again across all three metrics (Supplementary Figure 3). Detailed numerical data supporting these international comparisons are provided in Supplementary Tables 1−12. Figure 2ASIR, ASPR, and ASDaR of overall osteoarthritis in Germany compared to selected countries between 1990 and 2021.The figure contains three line graphs comparing overall osteoarthritis burden in Germany with selected countries from 1990 to 2021. The top graph shows the age-standardized incidence rate, the middle graph shows the age-standardized prevalence rate, and the bottom graph shows the age-standardized DALY rate, all per 100,000 persons. In each panel, the x-axis represents year and the y-axis represents the corresponding age-standardized rate. Countries shown include Brazil, Canada, China, Egypt, France, Germany, Iraq, Italy, Japan, Saudi Arabia, South Africa, the United Kingdom, and the United States of America. The graphs show differences between countries in both rate levels and temporal patterns over the study period.Three line graphs comparing age-standardized osteoarthritis incidence, prevalence, and DALY rates across Germany and various countries from 1990 to 2021. ASIR, ASPR, and ASDaR of overall osteoarthritis in Germany compared to selected countries between 1990 and 2021. Correlations Between Burden of OA and SDI ASIR demonstrated a significant positive temporal correlation with SDI (r = 0.94; p <0.001). Similarly, ASPR and ASDaR demonstrated significant positive temporal correlation with SDI (r = 0.91; p <0.001 and r = 0.88; p <0.001, respectively). Supplementary Figure 4 shows the significant positive temporal correlations between SDI and ASIR, ASPR, and ASDaR. Burden of OA by Age and Sex in 2021 The age-specific incidence rate of OA steadily rises from the 30–34 age and peaks at the 60–64 age group, before decreasing in older age groups. Age-specific incidence rates were higher for females compared to males (Supplementary Figure 5). The age-specific prevalence rate of OA steadily rises from the 30–34 age group and peaks at the 70+. The age-specific prevalence rates were higher for females than males for all age groups (Supplementary Figure 5). The age-specific DALY rate of OA steadily rises from the 30–34 age group and peaks at the 70+. The age-specific DALY rates were higher for females than males for all age groups (Supplementary Figure 5). Figure 3 demonstrates that Germany has higher age-specific DALY rates than the global average across both sexes, except for the 45 to 59 age group. Figure 3Germany-to-global age-specific DALY ratio by age group and sex in 1990 and 2021.The figure shows Germany-to-global age-specific DALY ratios for osteoarthritis in 1990 and 2021. The x-axis shows age groups from 30–34 years to 70+ years, and the y-axis shows the DALY ratio. Separate panels are shown for both sexes combined, females, and males. A horizontal reference line at 1.0 indicates equality between Germany and the global average. Values above 1.0 indicate higher age-specific DALY rates in Germany than the global average, while values below 1.0 indicate lower rates. Most age groups show ratios above 1.0, while the middle age groups around 45–59 years are closer to or slightly below 1.0.Multi-panel dot plot comparing age-specific DALY ratios across sexes and two time points. Germany-to-global age-specific DALY ratio by age group and sex in 1990 and 2021. Jointpoint Regression and Trend Analysis In terms of ASIR, our jointpoint regression model demonstrated statistically significant increases over the following periods: 1990–1994, 1994–2000, 2000–2005, 2010–2015 and 2019–2021. The period from 2005 to 2010 was the only frame in which significant decreases in ASIR were observed. On the other hand, the period from 2015 to 2019 demonstrated a stable trend. In terms of ASPR, our jointpoint regression model demonstrated significant increases throughout the following periods: 1990–1993, 1993–2000, 2000–2005, 2010–2014, 2014–2019, 2019–2021. Conversely, the 2005 to 2010 period demonstrated a significant decrease in ASPR. ASDaR showed a generally similar temporal pattern to ASPR over the study period. Figure 4 visually summarizes these trends, which presents the jointpoint regression analyses for ASIR, ASPR, and ASDaR from 1990 to 2021. Figure 4Jointpoint regression of ASIR, ASPR, and ASDaR of osteoarthritis from 1990 to 2021. (*indicates that the annual percent change (APC) is significantly different from zero at α = 0.05).The figure contains three jointpoint regression graphs for osteoarthritis in Germany from 1990 to 2021. The first graph shows ASIR, the second graph shows ASPR, and the third graph shows ASDaR. The x-axis represents year and the y-axis represents the corresponding age-standardized rate. Observed values are shown with trend segments representing different annual percent change periods. ASIR, ASPR, and ASDaR generally increased over the study period, with a decrease during 2005–2010 and renewed increases after 2010. Asterisks indicate annual percent changes that are statistically significantly different from zero at α = 0.05.Three jointpoint regression graphs showing trends in ASIR, ASPR, and ASDaR of osteoarthritis in Germany from 1990 to 2021. Jointpoint regression of ASIR, ASPR, and ASDaR of osteoarthritis from 1990 to 2021. (*indicates that the annual percent change (APC) is significantly different from zero at α = 0.05). Forecasting the Burden of OA to 2041 ARIMA modeling of ASIR attributed to OA demonstrated a continued upward trend. ASIR is expected to increase to 580.0 (95% CI: 554.7–605.3) per 100,000 persons by 2041 (ARIMA1,1,0; RMSE: 0.063; MAPE: 0.124). Similarly, ASPR attributed to OA is projected to increase, reaching 7309.1 (95% CI: 7110.9–7507.2) per 100,000 persons by 2041 (ARIMA1,1,0; RMSE: 0.211; MAPE: 0.412). Finally, ARIMA models projected an upward trend for ASDaR attributed to OA. By 2041, ASDaR is expected to reach 260.6 (95% CI: 252.3–268.9) per 100,000 persons (ARIMA1,1,0; RMSE: 0.168; MAPE: 0.261). Figure 5 illustrates the projected trends of ASIR, ASPR, and ASDaR attributed to osteoarthritis in Germany up to the year 2041, based on ARIMA modeling. The detailed yearly projection values used for these forecasts are provided in Supplementary Tables 13–15. Figure 5ARIMA-based projections of osteoarthritis burden in Germany to 2041; (A) ASIR, (B) ASPR, and (C) ASDaR and shaded areas indicate prediction intervals.The figure contains three ARIMA-based projection graphs showing osteoarthritis burden in Germany up to 2041. Panel A shows the age-standardized incidence rate, Panel B shows the age-standardized prevalence rate, and Panel C shows the age-standardized DALY rate. The x-axis represents year and the y-axis represents the corresponding age-standardized rate per 100,000 persons. The graphs show historical trends from 1990 to 2021 and projected values through 2041. All three measures are projected to continue increasing, reaching approximately 580.0 for ASIR, 7309.1 for ASPR, and 260.6 for ASDaR per 100,000 persons by 2041.Three graphs showing ARIMA-based projections of osteoarthritis ASIR, ASPR, and ASDaR in Germany to 2041. ARIMA-based projections of osteoarthritis burden in Germany to 2041; (A) ASIR, (B) ASPR, and (C) ASDaR and shaded areas indicate prediction intervals. Discussion Summary of Findings This study examined the burden of OA in Germany over a three-decade period using data from the GBD study. The results demonstrate a substantial increase in OA-related incidence, prevalence, and DALYs from 1990 to 2021. Relative increases were more marked among males, although females continued to have higher absolute incidence, prevalence, and DALY counts. OA incidence peaked in individuals aged 60–64, while prevalence and DALYs were highest in those aged 70 years and older. Notably, the onset of increased OA burden begins around the 30–34 age group, where age-specific incidence, prevalence, and DALY rates all start to rise significantly. The burden continues to increase with age, peaking later in life, and is consistently higher among females across all age brackets. Trends derived from Joinpoint regression identified key periods of accelerated burden, particularly after 2010. Moreover, knee OA was the dominant subtype, followed by hand and hip OA. Hip, knee, and other OA showed consistent increases in age-standardized incidence, prevalence, and DALY rates, whereas hand OA showed stable to declining age-standardized trends despite rising absolute case numbers. ASIR, ASPR, and ASDaR are projected to increase by 2041 based on ARIMA forecasting, which, in the context of an aging population, will result in a substantial increase in the absolute burden of OA over the coming decades. In Germany, the OA burden, was positively correlated with SDI. Age-specific DALY rates in Germany surpassed global averages for all age groups except 45–59 years, indicating a higher OA-related disability burden than the global norm. Contextualizing Findings Within the Literature The observed trends in Germany align closely with global patterns identified in recent GBD studies, which emphasize the growing burden of OA worldwide, particularly in high-SDI countries like Germany.1,17,18 The observed patterns are consistent with established epidemiological mechanisms, particularly the influence of age, sex-specific hormonal factors, and modifiable risks.4 Although OA has historically been more prevalent among females, the faster increase in burden among German male patients may reflect changes in health-seeking behavior, occupational exposure, and lifestyle. In addition, although females continued to carry a higher absolute DALY burden in 2021, the relative increase in DALYs was substantially greater among males. These findings are in line with previous research among adults aged 30 to 44 years, which found a higher increase in the recent years in both age-standardized incidence and prevalence in male compared to the females and which may partly reflect changes in BMI distribution and occupational exposure among males.24 Globally based on GBD 2019 data, it is projected that the ASIR is going to decrease in female in 2030 compared to 2019 but there would be an increase among male patients.18 Germany’s relatively lower ASIR compared with countries such as Japan, the United Kingdom, and the United States should be interpreted cautiously. Cross-country differences in GBD estimates may reflect true variation in OA risk, including differences in BMI distribution, occupational and mechanical joint loading, injury patterns, physical activity, and behavioral factors, but may also reflect differences in healthcare utilization, diagnostic coding, data availability, and modelled estimation. The GBD osteoarthritis study similarly notes that international variation may be influenced by genetic, metabolic, behavioral, and occupational factors, as well as limitations related to sparse and heterogeneous input data.1 Moreover, the positive temporal correlation between OA burden and the SDI, is consistent with the hypothesis that environmental and lifestyle factors associated with socioeconomic development may co-vary with OA burden, though this temporal co-variation cannot be interpreted as evidence of a causal relationship.5,17,25 Another GBD-based study concluded that high BMI stands out as a crucial modifiable risk factor significantly driving the global burden of osteoarthritis, with its impact notably more pronounced in regions with higher SDI levels.5 In addition to the overall increasing trend, the joinpoint regression identified a short-term decline in ASIR and ASPR between 2005 and 2010, followed by renewed increases after 2010. This pattern is important because it interrupts the otherwise long-term upward trend in OA burden in Germany. Several explanations may be considered. First, because GBD estimates are modelled using heterogeneous input sources, including population-based surveys and insurance-claims data, short-term changes may partly reflect differences in data availability, case definitions, coding practices, or model adjustments rather than a true biological reduction in OA occurrence. The GBD osteoarthritis study also notes that estimates may be influenced by diagnostic heterogeneity and data-source limitations.1 Second, changes in healthcare utilization may have influenced the recording of chronic diseases during this period. In 2004, Germany introduced the Praxisgebühr, a €10 quarterly charge for physician visits among adults insured through statutory health insurance. Previous analyses showed that this fee was associated with delayed or avoided physician visits, particularly among younger, healthier, and lower-income individuals, which may have reduced routine consultations for chronic, non-urgent conditions such as OA.26 A risk-factor explanation appears less likely as the main driver of this decline, as national German survey data from DEGS1 showed that overweight prevalence remained high and relatively stable, while obesity increased, particularly among men and young adults.27 Therefore, while a true epidemiological contribution cannot be entirely excluded, the observed decline between 2005 and 2010 should be interpreted cautiously as a short-term decrease that may reflect a combination of healthcare-utilization changes and GBD modelling characteristics, rather than clear evidence of a sustained reduction in OA occurrence. The renewed increase after 2010 supports the overall conclusion that OA burden in Germany has continued to rise over the long term. Among the six European countries studied (France, Germany, Italy, Spain, Sweden, and United Kingdom), Germany had the highest rates of hip and knee joint replacement surgeries in 2017, with 309 hip replacements and 223 knee replacements per 100,000 people.28 This is notable because Germany did not have the highest prevalence of OA among these countries. One possible explanation for this discrepancy is the lack of standardized indication criteria for joint replacement, which may lead to potential overtreatment in Germany or undertreatment in other countries.28,29 In a comprehensive analysis of osteoarthritis-related costs in Germany for the year 2002, direct medical costs were estimated at approximately €7.2 billion and indirect costs, primarily reflecting productivity losses from being unable to work and disability, were calculated at about €4.64 billion.30 Importantly, chronic pain in OA contributes significantly to healthcare utilization and costs. A German study involving over 238,000 OA patients found that those experiencing chronic pain nearly double the annual healthcare costs compared to those without chronic pain, averaging €6,801 versus €3,682.9 This financial burden stems from increased hospital admissions, outpatient visits, and prescription use.9 The study emphasizes the need for novel approaches to both prevent and manage chronic pain in OA to reduce the societal and economic impact of the disease.9 Implications of Projections to 2041 Projections of OA burden in Germany indicate a continued increase in incidence and overall burden, while the ARIMA model predicts a modest rise in age-standardized prevalence. These findings suggest a growing and sustained burden of disease, presenting critical challenges for future healthcare planning, resource allocation, and public health preparedness. While Germany’s total population is expected to decrease according to Destatis, both the average life expectancy and the proportion of people aged 67 and over are projected to rise.31 The health system will need to expand its capacity to manage chronic joint conditions and their associated disability. The growing demand for OA-related care will affect not only orthopedic services and surgical waiting lists but also long-term care, rehabilitation, and social support systems. This apparent divergence reflects the influence of demographic change, where population aging drives significant increases in absolute case numbers regardless of only modest increases in age-standardized rates. Specifically, the projected ASPR rises from approximately 7,102 to 7,309 per 100,000 over 20 years (a ~2.9% increase), indicating that disease risk per person is relatively stable; however, the absolute number of people affected will grow substantially as a larger proportion of the population enters older age groups. Policymakers should therefore focus on the absolute case burden when planning healthcare capacity, while recognising that prevention efforts aimed at modifiable risk factors remain relevant given the modest but persistent upward trend in age-standardized rates. In a study based on arthroplasty data from 2005 to 2016 provided by DeStatis, it was stated that even though Germany’s population is expected to decline, the number of primary total knee arthroplasties (TKA) is projected to increase by 45%, and primary total hip arthroplasties by 23% in 2040 compared to 2016.32 Notably, the largest increase in TKA procedures is expected among patients aged 40 to 49 years, with a projected rise of 269% by 2040 compared to 2016, while the greatest increase in THA procedures is anticipated in patients aged 80 to 89 years, with a 71% increase during the same period.32 In another study using the DeStatis between 2010 and 2019, they projected incidence rate of shoulder arthroplasty in Germany by 2040 is estimated to increase to between 47 or 112 per 100,000 inhabitants, depending on the modeling approach used, which represent a 175% increase since 2010.33 This increase in the shoulder arthroplasty is said to be higher than the increase in the hip and knee arthroplasty surgeries which is mainly attributed to the increase cases of fracture-related reverse total shoulder arthroplasty in elderly patients.33 Projections from a Markov illness-death model suggest that although diseases such as dementia and heart failure are anticipated to experience the most significant relative growth, back pain and arthrosis will account for the largest share of cases in Germany by 2060.34 The analysis estimates that OA will be the second most common chronic condition, with 13 to 15 million affected individuals, marking a 69.8% increase in prevalence from 2018 levels.34 This surge is attributed to population aging and persistent incidence rates, despite optimistic scenarios (eg., better prevention or delayed onset) is not enough to counterbalance the growing burden.34 These findings underscore the need for long-term strategic planning, including increased investment in musculoskeletal health, expansion of community-based OA care models, and public health interventions aimed at reducing the incidence and delaying disease progression. Without such planning, the health system may be overwhelmed by the needs of an increasingly older population living with chronic joint pain and disability. Challenges One of the most critical consequences of the sharply increasing OA burden projected by ARIMA models is the strain on Germany’s healthcare system. Furthermore, demographic aging further intensifies these challenges. The working-age population (ages 18–68) is expected to decline steadily over the coming decades, further shrinking the workforce available to support the healthcare system.8 According to the Central Institute for Statutory Health Insurance Physicians in Germany (Zi) in Germany, by around 2030, approximately 8,000 to 9,000 doctors are expected to retire each year due to age and the current numbers of new medical specialists being trained are insufficient to fully replace these retirees, leading to a projected shortage in the medical workforce.35 This trend has serious implications for healthcare sustainability, as fewer workers will be available to care for an expanding elderly population with chronic conditions like OA.13 Other studies have also highlighted the concerns about the aging workforce in orthopedics and trauma surgery, with a growing number of physicians approaching retirement age and insufficient numbers of new specialists being trained to replace them.13,36 This imbalance may result in longer waiting times for treatment including surgeries and reduced access to conservative therapies such as physiotherapy and intra-articular injections. Germany faces significant workforce constraints in healthcare, particularly in underserved regions.37–39 Forecasts by PricewaterhouseCoopers (PwC) project that the German healthcare sector will experience a substantial shortage of approximately 1.8 million healthcare professionals by the year 2035, corresponding to a supply gap of around 35%. This projected deficit poses a significant threat to the healthcare system’s capacity to provide timely and effective diagnosis and management of chronic multidisciplinary conditions such as OA.39 A nationwide survey of 185 department heads in orthopedic and trauma surgery in late 2022, revealed that over half (55%) had unfilled physician positions, with a median of 2.7 vacancies per department which equals about 20% of available positions.13 The emigration of doctors from Germany presents a challenging issue that must be carefully addressed to prevent adverse effects on the medical sector.40 A 2009 study highlighted that the number of German doctors leaving the country exceeds the number of foreign doctors immigrating, resulting in a net deficit that exacerbates the shortage of medical professionals.40 In a cross-sectional survey conducted in Saxony, Germany, in 2012 among physicians with German citizenship aged 40 years or younger, approximately 29.5% of participants expressed a wish to emigrate from Germany to work abroad.37 These findings point to acute staffing challenges that threaten the delivery of OA care in both hospitals and outpatient clinics. Moreover, the issue extends beyond the musculoskeletal health sector. For instance, the psychological diagnosis (ICD-10 chapter F) among OA patients in Germany increased between 2009 and 2019 with 37.8% for coxarthrosis and 17.9% for gonarthrosis, highlighting the growing mental health burden accompanying OA.41 Moreover, long-term sick leave in working-age adults aged 18–65 with OA in Germany is common with about 36.2% of newly diagnosed OA patients had long-term sick leave (more than 42 days) in the year following diagnosis.42 Additionally, the increased need for multidisciplinary care including physical therapy, pain management, and psychological support further strains healthcare resources.7,9,41 These findings underscore the importance of early intervention strategies and integrated care models to address both the physical and psychosocial dimensions of OA. The projected rise in OA-related care should also be viewed in the context of financial pressure on German hospitals. The Krankenhaus-Report 2024 and German Hospital Federation analyses describe a cumulative investment deficit approaching €9 billion, while rising personnel and energy costs and delayed DRG adjustments left approximately 96% of hospitals unable to fully cover their costs in 2023. These constraints may limit hospital capacity to respond to increasing demand for OA-related inpatient care, arthroplasty, and rehabilitation services.43 Recommendations Managing the rising burden of OA requires a comprehensive and well planned policy response. Public health strategies should emphasize primary prevention through the promotion of healthy lifestyles, including weight management, physical activity, joint injury prevention programs, and self-management education.44,45 Promoting BMI reduction is essential for the effective management and relief of osteoarthritis, particularly in weight-bearing joints such as the knees and hips. Furthermore, disparities in disability retirement caused by knee osteoarthritis across occupations are closely tied to education levels and physical job demands.46 The increase in OA among younger population observed in our study starting from the early 30s may reflect multiple interacting factors, including occupational and mechanical joint loading during working age, earlier diagnosis due to advancements in the medical system especially in high SDI countries, increased BMI, sedentary lifestyles, and unhealthy dietary patterns.24 To address this, targeted educational programs and workplace modifications aimed at minimizing physical strain could help reduce OA prevalence, particularly in high-risk professions.46 Improving access to evidence-based conservative care, including pharmacological and non- pharmacological interventions like structured exercise programs, weight management, and pain coping strategies (including cognitive behavioral therapy and self-management programs) should be a priority to delay surgical intervention and maintain quality of life for osteoarthritis patients.47 Psychological comorbidities such as depression and anxiety are common among OA patients in Germany and can worsen pain and functional limitations.41 Implementing effective screening tools, preventive strategies, and systematic depression management has been shown to reduce pain severity and improve overall outcomes.41 The 2019 Osteoarthritis Research Society International (OARSI) guidelines recommend a patient-centered, individualized treatment algorithm that incorporates comorbidity profiles and patient preferences, facilitating personalized and safer symptom management while delaying the need for surgical intervention.47 Continued investment in osteoarthritis research particularly in early diagnosis and disease-modifying therapies is critical to drive innovation and support these evolving care models. From an economic perspective, the projected increase in OA burden highlights the need to assess direct costs, including hospital care, arthroplasty, outpatient visits, medication, physiotherapy, and assistive devices, alongside indirect costs such as productivity loss, long-term sick leave, early retirement, and disability.48 Health economic evaluations and health technology assessments (HTA) should be integrated into OA planning to compare the value of prevention, conservative care, rehabilitation, and surgical interventions, and to guide efficient resource allocation as conservative and surgical OA-related care needs continue to rise.49 Given the projected significant increase in osteoarthritis age-standardized incidence, prevalence, and based on ARIMA models, along with the reported rise in surgical interventions in Germany, it is critical to strengthen and expand the healthcare workforce to meet the growing demand for comprehensive osteoarthritis treatment and to ensure the optimal use of both conservative and surgical management options.15 National strategy should focus on expanding training programs in orthopedics and trauma medicine, offering targeted incentives for physicians to work in underserved areas, and improving working conditions to enhance recruitment and retention, taking into consideration that the newer generations are increasingly interested in achieving a good work-life balance.13 More than two-thirds of orthopaedics and trauma surgery clinics in Germany already employ foreign-trained doctors who are non-native German speakers, yet a significant shortage of medical staff persists.13 Furthermore, to counteract the shortage, it is recommended to increase the number of medical study places, improving hospital working conditions (reducing administrative burden, improving training, adjusting remuneration), and enhancing student teaching to inspire enthusiasm for orthopaedics and trauma surgery.13 There is urgent need to facilitate the integration of internationally trained healthcare professionals by facilitating credential recognition and supporting rapid workforce integration.13,50 Prioritizing workforce diversity and addressing systemic barriers will be essential to alleviate shortages and ensure retention and quality of care in various medical fields, including orthopaedics and trauma surgery across all settings.50 Strengths and Limitations This study has several notable strengths. First, the utilization of comprehensive GBD 2021 data enabled a robust analysis of osteoarthritis trends over more than three decades, enhancing the reliability of observed temporal patterns. The large dataset size and standardized methodology of the GBD study lend particular credibility to our findings. Second, our application of advanced statistical methods, including Joinpoint regression, decomposition analysis, and ARIMA forecasting, provided a more detailed understanding of temporal trends, changes in trend direction, drivers of increasing burden, and future projected burden. Third, the inclusion of age- and sex-stratified analyses offers valuable insights into population-specific disparities in OA burden may inform future prevention and healthcare planning. However, several limitations should be considered when interpreting these findings. As with all studies using GBD data, our analysis relies on secondary data sources that may contain inherent biases due to differences in data availability, diagnostic practices, case definitions, and reporting methods over time. In particular, diagnostic criteria for osteoarthritis have evolved over the study period, which may influence apparent trends in age-standardized incidence and prevalence independent of actual disease patterns. Our projections to 2041 are based on current trends and assumptions that may not account for future changes in population structure, healthcare policy, prevention strategies, diagnostic behavior, or treatment access. Additionally, the study could not fully explore regional variations within Germany due to data limitations at the subnational level. In addition, statistical analyses such as EAPC, joinpoint regression, and correlation analyses were conducted using point estimates and did not incorporate the full uncertainty intervals of GBD modelled estimates, which should be considered when interpreting the findings. Furthermore, correlations between SDI and OA burden were based on within-country GBD time-series data and may reflect co-trending over time rather than a direct association. Therefore, these correlations should be interpreted descriptively and not as evidence of a causal relationship. Future Research Directions These limitations highlight the need for future research incorporating longitudinal, multi-center studies across different German regions to better understand local variability in OA prevalence and outcomes. Such studies could help clarify the impact of regional differences in genetics, lifestyle factors, environmental exposures, and healthcare access on disease progression and patient quality of life. Additionally, studies assessing the effectiveness of early intervention programs and digital health tools in improving OA outcomes will be essential in designing more responsive care models. Given the changing healthcare landscape, analyzing health systems can provide valuable insights into the future costs and resource needs of OA care. Understanding these factors will help policymakers plan for the sustainable delivery of musculoskeletal health services. Beyond health-systems research, the projected rise in OA burden highlights the need to advance innovative disease-modifying and regenerative strategies. Mesenchymal stem cell-based therapies and 3D bioprinting of osteochondral scaffolds are promising translational approaches for OA management and cartilage regeneration.51,52 However, further studies are needed to confirm their long-term efficacy, safety, feasibility for wider clinical use, and cost-effectiveness in the context of Germany’s growing OA burden. Conclusion This study highlights the significant and growing burden of osteoarthritis in Germany from 1990 to 2021, projected to continue rising through 2041, primarily driven by demographic aging. Incident cases, prevalent cases, and DALYs all increased, while ASIR, ASPR, and ASDaR showed significant upward trends. Although females continued to carry the higher absolute burden, relative increases were greater among males. The burden was higher in older adults, and knee OA remained the dominant subtype, accounting for the largest share of OA-related incidence, prevalence, and disability. Germany also showed higher age-specific OA-related DALY rates than global estimates in most age groups, supporting the relevance of OA as a national disability burden. ARIMA projections suggest that ASIR, ASPR, and ASDaR may continue to increase through 2041 if historical trends persist. The findings highlight the importance of continued surveillance, prevention strategies targeting modifiable risk factors, and healthcare planning for chronic musculoskeletal disability, particularly among older adults and population groups with increasing burden. While this study did not directly assess healthcare utilization, costs, or service capacity, the observed and projected epidemiological trends provide a strong basis for future health-services research. Further studies should examine how the rising OA burden varies across German regions and how it affects treatment access, rehabilitation needs, surgical care pathways, economic burden, and long-term health-system capacity.